From: SESN2 correlates with advantageous prognosis in hepatocellular carcinoma
Groups | No. | SESN2 | χ 2 | p value | |
---|---|---|---|---|---|
+ | % | ||||
Gender | |||||
Male | 83 | 31 | 37.3 | 0.088 | 0.767 |
Female | 17 | 7 | 41.2 | ||
Age (years) | |||||
< 60 | 58 | 18 | 31.0 | 2.844 | 0.092 |
≥ 60 | 42 | 20 | 47.6 | ||
Hepatitis B virus infection | |||||
Positive | 41 | 10 | 24.4 | 5.463 | 0.019* |
Negative | 59 | 28 | 47.5 | ||
Hepatitis C virus infection | |||||
Positive | 52 | 31 | 59.6 | 21.484 | 0.001* |
Negative | 48 | 7 | 14.6 | ||
Liver cirrhosis | |||||
Positive | 58 | 21 | 36.2 | 0.189 | 0.664 |
Negative | 42 | 17 | 40.5 | ||
Tumor size (cm) | |||||
> 5 | 57 | 19 | 33.3 | 1.225 | 0.268 |
≤ 5 | 43 | 19 | 44.2 | ||
Lymph node metastasis | |||||
Positive | 31 | 7 | 22.6 | 4.534 | 0.033* |
Negative | 69 | 31 | 44.9 | ||
Distant metastasis | |||||
Positive | 12 | 4 | 33.3 | 0.126 | 0.723 |
Negative | 88 | 34 | 38.6 | ||
TNM stage | |||||
Stage I-II | 41 | 17 | 41.5 | 0.354 | 0.552 |
Stage III-IV | 59 | 21 | 35.6 |